Biophan Announces Test Results of Proprietary Technology to Enable MRI Image Compatibility of Vascular Stents

ROCHESTER, N.Y.--(BUSINESS WIRE)--April 15, 2005--

Patented Technology Allows Safe and Accurate MRI Imaging of Stent Interior for Advanced Medical Diagnostics

“Biophan is currently working on combining Biophan-Europe's resonance technologies with Biophan's nanomagnetic thin-film coating technology to enable the production of improved, lower-profile stent devices. We believe this will ultimately provide the ideal solution for the stent industry”

Biophan Technologies, Inc. (OTC BB: BIPH), a developer of next-generation medical technology, today announced results from testing of the Company's patented technology that will enable magnetic resonance imaging (MRI) within vascular stents, allowing physicians for the first time to assess the health of stented arteries by means of non-invasive MRI technology. Biophan CEO Michael Weiner made the announcement.

Stents are used to expand, and keep open, blood vessels that have narrowed as a result of coronary artery disease. Stents are one of the most successful - and rapidly growing - medical devices in use today, and have been implanted in millions of patients worldwide to help ensure healthy blood flow. One of the most important types of stents, coronary stents, represents a multi-billion dollar market. Current stent technology presents certain significant diagnostic limitations that have been solved by Biophan's proprietary technology.

"Current stents are safe for use with MRI, particularly when patients are allowed a period of time after implantation before receiving an MRI, but are not MRI-compatible, and thus cannot be clearly imaged with MRI systems," said Dr. Michael Friebe, CEO of Biophan-Europe. "This is an important distinction, because it means that a patient with a stent can safely have an MRI procedure performed for another indication, such as a knee injury, but the MR image in the region around and within the stent is negatively affected by the implant. No current stent on the market allows visualization of blood clots or restenosis within the stent. Biophan's proprietary resonator technology can solve this problem, enabling an entirely new method of evaluating patients after stent implantation."

Currently, evaluation of restenosis within a stent requires an additional interventional procedure--either intravenous ultrasound or an angiography procedure involving the infusion of a potentially toxic contrast agent combined with imaging under x-ray. Both of these procedures require the insertion of a catheter and guidewire into the patient. Biophan's technology to enable MR imaging within a stent would allow a non-invasive diagnostic procedure to provide similar data, eliminating the need for catheterization of the patient, exposure of the patient to ionizing radiation to obtain the x-ray image, and exposure of the patient to contrast agents. The Biophan procedure would allow for safer, less invasive and less costly evaluation of this patient population.

The technology revealed today employs the Company's "active" MRI solutions that use proprietary resonant frequency circuitry to enable superior visualization within an MRI. The Biophan-Europe division, based in Germany and formerly known as AMRIS GmbH, developed the resonance circuit technology and is a leading innovator of medical devices and technology solutions for MRI, in which Biophan recently acquired a controlling interest.

"Biophan is currently working on combining Biophan-Europe's resonance technologies with Biophan's nanomagnetic thin-film coating technology to enable the production of improved, lower-profile stent devices. We believe this will ultimately provide the ideal solution for the stent industry," said Mr. Weiner.

The technology is demonstrated with actual MRI images, and illustrative graphics, in a slide presentation on the Company's website. To view the presentation, please visit http://www.biophan.com/presentations/MRIImage.ppt.

Mr. Weiner added that Biophan has recently achieved significant progress in the establishment of relationships with manufacturers of several medical devices. "I am pleased to have reached the agreement we were seeking with a preferred partner, achieving fair value for our technology. We look forward to announcing the specifics as soon as we are authorized to do so."

About Biophan Technologies

Biophan develops and markets cutting-edge technologies designed to make biomedical devices safe and compatible with the magnetic resonance imaging (MRI) environment. The Company develops enabling technologies for implanted medical systems such as pacemakers and interventional surgical devices such as catheters, guidewires, stents, and other implants to allow them to be safely and effectively imaged under MRI. The technology is also being used to create MRI contrast agents, and has expanded to include other applications, such as drug delivery and power systems derived from body heat. Four Biophan technologies include advances in nanotechnology and thin film coatings. Committed to growth through innovation and developmental leadership, Biophan and its licensors now hold a total of 114 U.S. patents, licenses, or applications. This total includes 36 issued U.S. patents, 6 recently-allowed applications that will issue as patents in the near future, and 72 pending applications at various stages of examination at the U.S. Patent and Trademark Office, plus international applications. The patents cover areas including nanotechnology (nanomagnetic particle coatings), radio frequency filters, polymer composites, thermoelectric materials for batteries generating power from body heat, and photonics. Biophan has joint development arrangements with Boston Scientific (NYSE:BSX - News) and NASA's Ames Center for Nanotechnology. Biophan's goal is to make all biomedical devices capable of safely and successfully working with MRI, and delivering other technologies which will improve quality of life. For more information, please visit www.biophan.com.

Cautionary Statement Regarding Forward-Looking Statements

Certain statements included in this press release may constitute forward-looking statements within the meaning of applicable securities laws. These statements reflect what Biophan anticipates, expects, or believes may happen in the future. Biophan's actual results could differ materially from the outcome or circumstance expressed or implied by such forward looking statements as a result of a variety of factors including, but not limited to: Biophan's ability to develop its technologies; the approval of Biophan's patent applications; the successful implementation of Biophan's research and development programs; the ability of Biophan to demonstrate the effectiveness of its technology; the acceptance by the market of Biophan's technology and products incorporating such technology, the ability of Biophan to effectively negotiate and enter into contracts with medical device manufacturers for the licensing of Biophan's technology; competition; the ability of Biophan to raise capital to fund its operating and research and development activities until it generates revenues sufficient to do so; and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in Biophan's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with Biophan's periodic filings with the SEC which are incorporated herein by reference. The forward-looking statements contained herein are made only as of the date of this press release, and Biophan undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.